The role of the central renin-angiotensin system in Parkinson’s disease

Abstract

Since the discovery of a renin-angiotensin system (RAS) in the brain, several studies have linked this central RAS to neurological disorders such as ischaemia, Alzheimer’s disease and depression. In the last decade, evidence has accumulated that the central RAS might also play a role in Parkinson’s disease. Although the exact cause of this progressive neurodegenerative disorder of the basal ganglia remains unidentified, inflammation and oxidative stress have been suggested to be key factors in the pathogenesis and the progression of the disease. Since angiotensin II is a pro-inflammatory compound that can induce the production of reactive oxygen species due to activation of the NADPH-dependent oxidase complex, this peptide might contribute to dopaminergic cell death. In this review, three different strategies to interfere with the pathogenesis or the progression of Parkinson’s disease are discussed. They include inhibition of the angiotensin-converting enzyme, blockade of the angiotensin II type 1 receptor and stimulation of the angiotensin II type 2 receptor.

Keywords

angiotensin II type 1 receptor antagonists angiotensin II type 2 receptor agonists angiotensin-converting enzyme inhibitors neuroprotection Parkinson’s disease

Get full access to this article

View all access options for this article.

References

Culman J. , Blume A. , Gohlke P. et al. The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers. J Hum Hypertens 2002;16(suppl 3): S64-70.

Fischer-Ferraro C. , Nahmod VE , Goldstein DJ et al. Angiotensin and renin in rat and dog brain. J Exp Med 1971;133:353-61.

Stragier B. , De Bundel D. , Sarre S. et al. Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. Heart Fail Rev 2008;13:321-37.

Phillips MI , de Oliveira EM Brain renin angiotensin in disease. J Mol Med 2008;86:715-22.

Dunnett SB , Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson’s disease. Nature 1999;399(6738 suppl):A32-9.

Johnston TH , Brotchie JM Drugs in development for Parkinson’s disease. Curr Opin Investig Drugs 2004;5:720-6.

O’Neill MJ , Messenger MJ , Lakics V. et al. Neuro-replacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson’s disease . Int Rev Neurobiol 2007;77:179-217.

Jenner P. , Olanow CW Understanding cell death in Parkinson’s disease. Ann Neurol 1998;44(3 suppl 1):S72-84.

Andersen JK

Oxidative stress in neurodegeneration: cause or consequence?

Nat Med 2004;10(suppl):S18-25.

10.

Block ML , Hong JS Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005;76(2):77-98.

11.

Rodriguez-Pallares J. , Parga JA , Munoz A. et al. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J Neurochem 2007;103:145-56.

12.

Rodriguez-Pallares J. , Rey P. , Parga JA et al. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis 2008;31(1):58-73.

13.

Gao HM , Hong JS , Zhang W. et al. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2002;22:782-90.

14.

Gao HM , Liu B. , Hong JS Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2003;23:6181-7.

15.

Wu DC , Teismann P. , Tieu K. et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Proc Natl Acad Sci U S A 2003;100:6145-50.

16.

van Muiswinkel FL , de Vos RA , Bol JG et al. Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 2004;25: 1253-62.

17.

Suzuki Y. , Ruiz-Ortega M. , Lorenzo O. et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003;35:881-900.

18.

Griendling KK , Sorescu D. , Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501.

19.

Griendling KK , Ushio- Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 2000; 91(1-3):21-7.

20.

Unger T. , Badoer E. , Ganten D. et al. Brain angiotensin: pathways and pharmacology. Circulation 1988;77:140-54.

21.

Strittmatter SM , Thiele EA , Kapiloff MS et al. A rat brain isozyme of angiotensin-converting enzyme. Unique specificity for amidated peptide substrates. J Biol Chem 1985;260: 9825-32.

22.

Skidgel RA , Erdos EG The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens 1987;9:243-59.

23.

Chai SY , Mendelsohn FA , Paxinos G. Angiotensin converting enzyme in rat brain visualized by quantitative in vitro autoradiography. Neuroscience 1987;20:615-27.

24.

Chai SY , McKenzie JS , McKinley MJ et al. Angiotensin converting enzyme in the human basal forebrain and midbrain visualized by in vitro autoradiography. J Comp Neurol 1990;291:179-94.

25.

Konings CH , Kuiper MA , Bergmans PL et al. Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson’s disease. Clin Chim Acta 1994;231:101-06.

26.

Jenkins TA , Mendelsohn FA , Chai SY Angiotensin-converting enzyme modulates dopamine turnover in the striatum . J Neurochem 1997;68:1304-11.

27.

Reardon KA , Mendelsohn FA , Chai SY et al. The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson’s disease. Aust N Z J Med 2000;30(1):48-53.

28.

Ehlers MR , Riordan JF Angiotensin-converting enzyme: new concepts concerning its biological role . Biochemistry 1989;28:5311-18.

29.

Lin JJ , Yueh KC , Chang DC et al. Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson’s disease. J Neurol Sci 2002;199(1-2):25-9.

30.

Barker R.

Substance P and Parkinson’s disease: a causal relationship?

J Theor Biol 1986;120:353-62.

31.

Mellick GD , Buchanan DD , McCann S. et al. The ACE deletion polymorphism is not associated with Parkinson’s disease. Eur Neurol 1999;41:103-06.

32.

Pascale E. , Purcaro C. , Passarelli E. et al. Genetic polymorphism of angiotensin-converting enzyme is not associated with the development of Parkinson’s disease and of L-dopa-induced adverse effects. J Neurol Sci 2009;276(1-2):18-21.

33.

Chabrashvili T. , Kitiyakara C. , Blau J. et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol 2003; 285:R117-24.

34.

Jenkins TA , Wong JY , Howells DW et al. Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse. J Neurochem 1999;73:214-19.

35.

Kurosaki R. , Muramatsu Y. , Kato H. et al. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice. Eur Neuropsychopharmacol 2005;15(1):57-67.

36.

Munoz A. , Rey P. , Guerra MJ et al. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism . Neuropharmacology 2006;51:112-20.

37.

Lopez-Real A. , Rey P. , Soto-Otero R. et al. Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of parkinsonism. J Neurosci Res 2005;81:865-73.

38.

Babior BM NADPH oxidase: an update. Blood 1999; 93:1464-76.

39.

Babior BM NADPH oxidase. Curr Opin Immunol 2004;16(1):42-7.

40.

Munzel T. , Keaney JF Jr.

Are ACE inhibitors a "magic bullet" against oxidative stress?

Circulation 2001;104:1571-4.

41.

Beckman JS , Beckman TW , Chen J. et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990;87:1620-4.

42.

Zimmerman MC , Davisson RL Redox signaling in central neural regulation of cardiovascular function. Prog Biophys Mol Biol 2004;84:125-49.

43.

Okamura A. , Rakugi H. , Ohishi M. et al. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999 ;17:537-45.

44.

Yanagitani Y. , Rakugi H. , Okamura A. et al. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 1999;33:335-9.

45.

Qin L. , Liu Y. , Wang T. et al. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 2004;279:1415-21.

46.

Touyz RM Reactive oxygen species and angiotensin II signaling in vascular cells - implications in cardiovascular disease. Braz J Med Biol Res 2004;37:1263-73.

47.

Rajagopalan S. , Kurz S. , Munzel T. et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.

48.

Griendling KK , Minieri CA , Ollerenshaw JD et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-8.

49.

Sun C. , Sellers KW , Sumners C. et al. NAD(P)H oxidase inhibition attenuates neuronal chronotropic actions of angiotensin II. Circ Res 2005;96:659-66.

50.

Yamamoto E. , Tamamaki N. , Nakamura T. et al. Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation. Stroke 2008;39:3049-56.

51.

Rey P. , Lopez-Real A. , Sanchez-Iglesias S. et al. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol Aging 2007;28: 555-67.

52.

Mak IT , Freedman AM , Dickens BF et al. Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 1990;40:2169-75.

53.

Noda Y. , Mori A. , Packer L. Free radical scavenging properties of alacepril metabolites and lisinopril . Res Commun Mol Pathol Pharmacol 1997;96:125-36.

54.

Mira ML , Silva MM , Queiroz MJ et al. Angiotensin converting enzyme inhibitors as oxygen free radical scavengers. Free Radic Res Commun 1993;19:173-81.

55.

Suzuki S. , Sato H. , Shimada H. et al. Comparative free radical scavenging action of angiotensin-converting enzyme inhibitors with and without the sulfhydryl radical. Pharmacology 1993;47(1):61-5.

56.

Fernandes AC , Filipe PM , Freitas JP et al. Different effects of thiol and nonthiol ACE inhibitors on copper-induced lipid and protein oxidative modification. Free Radic Biol Med 1996;20:507-14.

57.

Obata T. , Takahashi S. , Kashiwagi Y. et al. Protective effect of captopril and enalaprilat, angiotensin-converting enzyme inhibitors, on para-nonylphenol-induced *OH generation and dopamine efflux in rat striatum. Toxicology 2008;250(2-3): 96-9.

58.

Stocchi F. , Olanow CW Neuroprotection in Parkinson’s disease: clinical trials. Ann Neurol 2003;53(suppl 3):S8797;discussion S-9.

59.

Warnholtz A. , Munzel T. Why do antioxidants fail to provide clinical benefit? Curr Control Trials Cardiovasc Med 2000;1(1):38-40.

60.

Mendelsohn FA , Jenkins TA , Berkovic SF Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res 1993;613:221-9.

61.

Brown DC , Steward LJ , Ge J. et al. Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br J Pharmacol 1996;118:414-20.

62.

Allen AM , MacGregor DP , Chai SY et al. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann Neurol 1992;32: 339-44.

63.

Allen AM , Moeller I. , Jenkins TA et al. Angiotensin receptors in the nervous system. Brain Res Bull 1998;47(1):17-28.

64.

Daubert DL , Meadows GG , Wang JH et al. Changes in angiotensin II receptors in dopamine-rich regions of the mouse brain with age and ethanol consumption. Brain Res 1999;816(1):8-16.

65.

Simonnet G. , Giorguieff-Chesselet MF , Carayon A. et al. Angiotensin II and nigostriatal system. J Physiol Paris 1981;77(1):71-9.

66.

Ge J. , Barnes NM Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. Eur J Pharmacol 1996; 297: 299-306.

67.

Grammatopoulos TN , Jones SM , Ahmadi FA et al. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol Neurodegener 2007;2:1.

68.

Steckelings UM , Kaschina E. , Unger T. The AT2 receptor- a matter of love and hate . Peptides 2005;26:1401-09.

69.

Grammatopoulos TN , Ahmadi F. , Jones SM et al. Angiotensin II protects cultured midbrain dopaminergic neurons against rotenone-induced cell death. Brain Res 2005; 1045(1-2):64-71.

70.

Gohlke P. , Von Kugelgen S. , Jurgensen T. et al. Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats. J Hypertens 2002;20: 909-18.

71.

Becker C. , Jick SS , Meier CR Use of antihypertensives and the risk of Parkinson disease. Neurology 2008;70:1438-44.

72.

Grady EF , Sechi LA , Griffin CA et al. Expression of AT2 receptors in the developing rat fetus. J Clin Invest 1991;88: 921-33.

73.

Nielsen AH , Schauser K. , Winther H. et al. Angiotensin II receptors and renin in the porcine uterus: myometrial AT2 and endometrial AT1 receptors are down-regulated during gestation. Clin Exp Pharmacol Physiol 1997;24:309-14.

74.

de Gasparo M. , Catt KJ , Inagami T. et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-72.

75.

Song K. , Allen AM , Paxinos G. et al. Mapping of angiotensin II receptor subtype heterogeneity in rat brain. J Comp Neurol 1992;316:467-84.

76.

Lenkei Z. , Palkovits M. , Corvol P. et al. Distribution of angiotensin II type-2 receptor (AT2) mRNA expression in the adult rat brain. J Comp Neurol 1996 ;373:322-39.

77.

Lenkei Z. , Palkovits M. , Corvol P. et al. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front Neuroendocrinol 1997;18:383-439.

78.

Nuyt AM , Lenkei Z. , Palkovits M. et al. Ontogeny of angiotensin II type 2 receptor mRNA expression in fetal and neonatal rat brain. J Comp Neurol 1999 ;407:193-206.

79.

Nuyt AM , Lenkei Z. , Corvol P. et al. Ontogeny of angiotensin II type 1 receptor mRNAs in fetal and neonatal rat brain. J Comp Neurol 2001;440:192-203.

80.

von Bohlen und Halbach O. , Albrecht D. The CNS renin-angiotensin system. Cell Tissue Res 2006;326:599-616.

81.

Wright JW , Harding JW Important role for angiotensin III and IV in the brain renin-angiotensin system . Brain Res Brain Res Rev 1997;25(1):96-124.

82.

Gendron L. , Payet MD , Gallo-Payet N. The angiotensin type 2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms. J Mol Endocrinol 2003; 31:359-72.

83.

Reinecke K. , Lucius R. , Reinecke A. et al. Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kappaB. FASEB J 2003 ;17:2094-6.

84.

Cote F. , Do TH , Laflamme L. et al. Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J Biol Chem 1999;274:31686-92.

85.

Laflamme L. , Gasparo M. , Gallo JM et al. Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect counteracted by the AT1 receptors. J Biol Chem 1996;271:22729-35.

86.

Meffert S. , Stoll M. , Steckelings UM et al. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol 1996; 122(1):59-67.

87.

Stroth U. , Meffert S. , Gallinat S. et al. Angiotensin II and NGF differentially influence microtubule proteins in PC12W cells: role of the AT2 receptor. Brain Res Mol Brain Res 1998;53:187-95.

88.

Li J. , Culman J. , Hortnagl H. et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005;19:617-19.

89.

Rodriguez-Pallares J. , Quiroz CR , Parga JA et al. Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors. Eur J Neurosci 2004;20:1489-98.

90.

Sohn HY , Raff U. , Hoffmann A. et al. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br J Pharmacol 2000;131:667-72.

91.

Kaschina E. , Grzesiak A. , Li J. et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 2008 ;118:2523-32.

92.

Hu C. , Dandapat A. , Chen J. et al. Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. Atherosclerosis 2008;199: 288-94.

93.

Okada H. , Inoue T. , Kikuta T. et al. A possible anti-inflammatory role of angiotensin II type 2 receptor in immune-mediated glomerulonephritis during type 1 receptor blockade. Am J Pathol 2006;169:1577-89.

94.

Grammatopoulos TN , Outeiro TF , Hyman BT et al. Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro. Biochem Biophys Res Commun 2007;363:846-51.

95.

Wan Y. , Wallinder C. , Plouffe B. et al. Design, synthesis, and biological evaluation of the first selective non-peptide AT2 receptor agonist. J Med Chem 2004;47: 5995-6008.